CDK2 and gastric cancer: Our previous study showed that by decreasing the expression of cyclin-dependent kinase (CDK) 1 and CDK2, the miR-106a inhibitors arrested gastric cancer cells at the G0/G1 and G2/M phases and then suppressed cell proliferation; and the results of animal experiments showed that the miR-106a inhibitors significantly suppressed tumor growth in a dose-dependent manner26.